Olanzapine

May decrease blood glucose lowering effect of LANTUS. Dosage increases and increased glucose monitoring may be required.

Antipsychotic that increases risk for Parkinsonism, NMS, and akathisia when used concomitantly with tetrabenazine.

Enhanced antihypertensive effect when combined with olanzapine.

Co-administration potentiates orthostatic hypotension observed with olanzapine.

Potent CYP1A2 inducer causing approximately 50% increase in olanzapine clearance; higher doses may cause greater increase.

Activated charcoal reduces the maximum concentration and AUC of oral olanzapine.

Reduces olanzapine Cmax and AUC by about 60%; may be useful for olanzapine overdose treatment.

Diazepam: May potentiate orthostatic hypotension ( 7.1, 7.2 ) Alcohol: May potentiate orthostatic hypotension ( 7.1 ) Carbamazepine: Increased clearance of olanzapine ( 7.1) Fluvoxamine: May increase olanzapine levels ( 7.1 ) Olanzapine and Fluoxetine in Combination: Also refer to the DrugInteractions section of the package insert for Symbyax. (7.1) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs and alcohol ( 7.2 ) Antihypertensive Agents: Enhanced antihypertensive effect ( 7.2 ) Levodopa and Dopamine Agonists: May antagonize levodopa/dopamine agonists (7.2 ) Other Concomitant Drug Therapy: When using olanzapine in combination with lithium or valproate, refer to the Drug Interactions sections of the package insert for those products ( 7.2 ) 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2) ]. Diazepam — Olanzapine did not influence the pharmacokinetics of diazepam or its active metabolite N-desmethyldiazepam.

Olanzapine may antagonize dopamine agonists.

Coadministration produced a decrease in DSST scores. No alteration in pharmacokinetics of either drug.

When used in combination with fluoxetine, refer to package inserts for both drugs.

Fluoxetine combined with olanzapine requires monitoring; refer to Symbyax package insert.

CYP1A2 inhibitor decreases olanzapine clearance, increasing Cmax by 54% (female nonsmokers) to 77% (male smokers); lower olanzapine doses recommended.

Atypical antipsychotic that may reduce glucose-lowering effect of glimepiride, leading to worsening glycemic control.

May reduce glucose-lowering effect of glipizide, leading to worsening glycemic control; monitor closely.

Atypical antipsychotic that may decrease the blood glucose lowering effect. Dose adjustment and increased glucose monitoring required.

May decrease blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required.

Atypical antipsychotic that may decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

Atypical antipsychotic that may decrease blood glucose-lowering effect; dosage increases and increased glucose monitoring may be required.

May decrease blood glucose lowering effect of insulin detemir. Dosage increases and increased glucose monitoring may be required.

Atypical antipsychotic that may decrease the blood glucose lowering effect. Dose increases and increased glucose monitoring may be required.

Atypical antipsychotic that may decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

Atypical antipsychotic that may decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

Atypical antipsychotic that may decrease blood glucose lowering effect; dose adjustment and increased glucose monitoring may be required.

May decrease blood glucose lowering effect of Awiqli. Dose increases and increased glucose monitoring may be required.

Atypical antipsychotic that may decrease blood glucose lowering effect; dose adjustment and increased glucose monitoring required.

Atypical antipsychotic that may decrease blood glucose lowering effect. Dose increases and increased glucose monitoring may be required.

Olanzapine may antagonize levodopa effects.

IM lorazepam increases somnolence when combined with IM olanzapine.

May cause an increase in olanzapine clearance.

Atypical antipsychotic that may decrease blood glucose lowering effect. Repaglinide dose increases and increased glucose monitoring may be required.

May cause an increase in olanzapine clearance.

Warfarin does not affect olanzapine pharmacokinetics.

Diazepam — Olanzapine did not influence the pharmacokinetics of diazepam or its active metabolite N-desmethyldiazepam.

When using olanzapine in combination with lithium, refer to the Drug Interactions section of lithium package insert.

When using olanzapine in combination with valproate, refer to the Drug Interactions section of valproate package insert.